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Background: Our pilot study using miRNA PCR array found that miRNA-29b (miR-29b) is differentially expressed in
primary cultured CD133-positive A549 cells compared with CD133-negative A549 cells.
Methods: Ten human non-small cell lung cancer (NSCLC) cell lines and samples from thirty patients with NSCLC
were analyzed for the expression of miR-29b by quantitative RT-PCR. Bioinformatics analysis combined with tumor
metastasis PCR array showed the potential target genes for miR-29b. miR-29b lentivirus and inhibitors were transfected
into NSCLC cells to investigate its role on regulating cell proliferation which was measured by CCK-8 assay in vitro and
nude mice xenograft tumor assay in vivo. Cell motility ability was evaluated by transwell assay. The target genes
of miR-29b were determined by luciferase assay, quantitative RT-PCR and western blot.
Results: Bioinformatics analysis combined with tumor metastasis PCR array showed that matrix metalloproteinase
2 (MMP2) and PTEN could be important target genes of miR-29b. The expression of miR-29b was down regulated
in NSCLC tissues compared to the normal tissues. Clinicopathological analysis demonstrated that miR-29b had
significant negative correlation with lymphatic metastasis. The gain-of-function studies revealed that ectopic
expression of miR-29b decreased cell proliferation, migration and invasion abilities of NSCLC cells. In contrasts,
loss-of-function studies showed that inhibition of miR-29b promoted cell proliferation, migration and invasion of
NSCLC cells in vitro. Nude mice xenograft tumor assay confirmed that miR-29b inhibited lung cancer growth
in vivo. High-invasion (A549-H) and low-invasion (A549-L) NSCLC cell sublines from A549 cells were created by
using the repeated transwell assay aimed to confirm the effect of miR-29b on migration and invasion of NSCLC.
Furthermore, the dual-luciferase reporter assay demonstrated that miR-29b inhibited the expression of the luciferase
gene containing the 3’-UTRs of MMP2 and PTEN mRNA. Western blotting and quantitative RT-PCR indicated that
miR-29b down-regulated the expression of MMP2 at the protein and mRNA levels.
Conclusion: Taken together, our results demonstrate that miR-29b serves as a tumor metastasis suppressor, which
suppresses NSCLC cell metastasis by directly inhibiting MMP2 expression. The results show that miR-29b may be a
novel therapeutic candidate target to slow NSCLC metastasis.
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Lung cancer is characterized by a low survival and high
relapse rate after surgery [1, 2]. NSCLC, the most fre-
quently occurring category of lung cancer, accounts for
approximately 80 % of all cases [3]. Tumor invasion and
metastasis are the main factors responsible for NSCLC
treatment failure [4, 5].
Emerging evidence has revealed that microRNAs
(miRNAs) play key roles in various biological processes,
including metastasis, proliferation, apoptosis, stress re-
sistance, tumorigenesis, and cell differentiation [6, 7].
Compared with normal tissues, different tumors have
distinct miRNA expression characteristics. It has been
determined that abnormal miRNA expression is a crit-
ical carcinogenesis signal. In tumors, miRNAs perform
functions similar to those of oncogenes and tumor sup-
pressors. miRNA expression patterns are more finely
regulated than those of proteins [8]. Given these find-
ings, miRNA may have great potential as a biomarker in
early tumor diagnosis and treatment targets [9]. Many
studies have attempted to identify the metastasis-related
miRNAs in metastatic tumors using miRNA microarrays
analysis. For example, several miRNAs have been identi-
fied to be involved in development of NSCLC metasta-
sis, including let-7 [10], miR-200 [11], miR-125b [12]
and miR-10b [13]. Although miRNAs have been the sub-
ject of extensive research in recent years, the molecular
regulatory mechanisms of miRNAs and their effects on
cancer are not well understood.
In the present study, to screen the metastasis-related
miRNAs of NSCLC, CD133-positive and CD133-negative
subpopulation from human lung adnocarcinoma A549 cells
were isolated through immunomagnetic bead separation
method. CD133 has been considered a specific stem cell
marker and NSCLC prognosis marker [14, 15]. CD133-
positive cells have greater potential for proliferation,
metastasis, and chemo-radioresistance [16–18]. Through
bioinformatics analysis and miRNA PCR array and tumor
metastasis PCR array, PTEN, ETV4, COL4A2 and MMP2
were logically been speculated as miR-29b target genes.
Our results showed that miR-29b inhibited growth and me-
tastasis of NSCLC cells in vitro and in vivo. Additionally,
dual-luciferase reporter assay and western blot results fur-
ther elucidated that the miR-29b inhibited the expression of
the luciferase gene containing the 3’-UTRs of MMP2 and
PTEN mRNA. While miR-29b down-regulated the expres-
sion of MMP2 at the protein and mRNA levels. The results
showed that miR-29b maybe a novel therapeutic candidate
target or strategy for seeking to control NSCLC metastasis.
Methods
Tissue samples, cell culture and animals
Information about tissue specimens, NSCLC cell lines
and animals is given in the Additional file 1.Microarray screening of differentially expressed genes
between CD133-positive/negative NSCLC cells
Detailed information about isolation of CD133-positive/
negative A549 cells and microarray screening of differen-
tially expressed genes is provided in the Additional file 1.
Bioinformatics analysis
Using “miRNA” as the index word for predicting target
genes in the TargetScan (www.targetscan.org), PicTar
(www.pictar.org), and miRanda (www.microrna.org) da-
tabases, target genes were identified from overlapping
results from the three databases. Subsequently, we ex-
tracted the overlap of these results with that of the
tumor metastasis PCR array.
Quantitative RT-PCR
Quantitative RT-PCR was performed using kits for U6
and mature miR-29b (ABI, Foster City, CA, USA), accord-
ing to the manufacturer’s instructions. SYBR green real-
time RT-PCR was performed to detect MMP2 and PTEN.
Detailed information is provided in the Additional file 1.
Transfection studies
All miRNA duplexes (Additional file 2: Table S1) were
purchased from Genepharma (Shanghai, P.R. China).
H460 cells were transfected with inhibitor or inhibitor
NC at a final concentration of 100 nmol/L using Lipo-
fectamine RNAiMAX instructions (Invitrogen). A549
subline stably expressing miR-29b (A549-miR-29b) and
its control line (A549-NC) were established as described
in the Additional file 1.
Western blotting
The cells were lysed with radioimmunoprecipitation
assay buffer (Beyotime, Shanghai, China). The antibodies
used for western blotting are described in the Additional
file 1.
Plasmid construction
We purchased psiCHECK-2 plasmids from Promega
(Madison, WI, USA). Human genome DNA was used as
the template for the MMP2 3’ untranslated region
(UTR) and PTEN 3’ UTR PCR. XhoI and NotI restric-
tion sites were introduced at the 5’ ends of both the for-
ward and reverse primers (Additional file 2: Table S1).
Following double digestion, the linear psiCHECK-2 frag-
ment was connected with the 3’ UTRs using T4 DNA
ligase; positive clones were selected for sequencing valid-
ation after transformation. The sequencing-validated,
target recombinant plasmid was designated psiCHECK-
2-Wt-MMP2/PTEN-3’ UTR, and was used as a template
for constructing psiCHECK-2-Mut-MMP2/PTEN-3’ UTR
using antisense PCR and a site-specific mutagenesis kit
(Toyobo, Osaka, Japan).
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Plasmid (0.5 μg) and 50 nmol/L miR-29b mimic/mimic
NC were cotransfected using Lipofectamine LTX reagent
(Invitrogen). Three replicates and three parallel lines
were used each time. Following 48-h transfection, lucif-
erase activity was measured using a GloMax 20/20
Luminometer (Promega) according to the dual luciferase
reporting system instructions. Relative luciferase activity
was compared using the ratio of Renilla reniformis and
firefly luciferase activity (Rn/Ff).
Cell proliferation assay
To measure the effect of miRNA and inhibitor on cellu-
lar proliferation rates, cells were incubated in 10 %
CCK-8 (DOJINDO) diluted in normal culture media at
37 °C until visual color conversion appears. Proliferation
rates were determined at 24, 48, 72, 96, 120 h post-
transfection, and quantification was done on a microplate
reader set according to the manufacturer’s protocol.
In vitro assays of migration and invasion
The 24-well Boyden chamber with 8-μm pore size poly-
carbonate membrane (Corning, NY) was used to analyze
the migration and invasion of tumor cells. Details are in
the Additional file 1.
In vivo studies
H460 subline stably knockdown miR-29b (H460-LV-
miR-29b inhibitor) and its control line (H460-LV-CON),
were established as described in Additional file 1. Ana-
lysis for tumorigenicity was performed as described in
Additional file 1.
Statistical analysis
All data were analyzed using SPSS 13.0 (SPSS Inc, Chicago,
IL, USA); A paired t test was used to investigate the differ-
ence in the expression level of miR-29b between normal
and cancerous tissues. A 2-sample t test was used to
analyse the clinicopathologic characteristics of miR-29b
expression in the tissues of patients with NSCLC.
Quantitative RT-PCR, CCK-8 assay, migration and in-
vasion assay, and luciferase reporter assay were tested
using 1-way analysis of variance for factorial design.
P value < 0.05 was considered statistically significant.
Results
Screening and identifying the metastasis-related miRNAs
and target genes of NSCLC
To explore the miRNAs related to NSCLC metastasis,
miRNA PCR array (MAH-3100A detected 376 human
disease–related miRNA) were used to evaluate miRNA
expression in primary cultured CD133-positive/negative
A549 cells. Fourteen miRNAs were found up-regulated
and thirty-seven miRNAs were down-regulated in CD133-positive cells (Fig. 1a, Additional file 3: Table S2). The hu-
man tumor metastasis PCR array (PAHS-028A detected
84 metastasis-related genes) was used to further deter-
mine the metastasis-related genes that could be controlled
by CD133-regulated miRNAs. Nineteen metastasis-related
genes were found up-regulated in CD133-positive cells
(Fig. 1b, Additional file 4: Table S3). Finally, the target
genes of significantly different miRNAs were predicted by
bioinformatics analysis. The overlap genes were found be-
tween bioinformatics predicted analysis and tumor metas-
tasis PCR array. Among the predicted target genes of the
seven down-regulated miRNAs in CD133-positive A549
cells, the tumor metastasis PCR array contained four
target genes of miR-29b (Fig. 1c). MiR-29b was down-
regulated 7.6-fold in CD133-positive cells. however, its
putative target genes PTEN, ETV4, COL4A2, and
MMP2 were up-regulated 1.11 to 4.2-fold. Based on
PTEN and MMP2 were reported closely related to metas-
tasis process, these two genes were further investigated to
confirm their regulation by miR-29b in NSCLC.
miR-29b is down-regulated in NSCLC tissues
Quantitative RT-PCR results revealed that the expres-
sion levels of miR-29b were significantly higher in the
H460 and 95C cell lines compared to 16HBE cell line,
while the expression levels were lower in the PGCL3,
PAa, H520, A549, H1299 and 95D cell lines (Fig. 2a).
Twenty pairs of paraffin-embedded NSCLC tissues and
normal tissues (Fig. 2b) and ten pairs of fresh NSCLC
tissues and normal adjacent tissues (Fig. 2c) were also
chosen to detect the expression levels of miR-29b, the
results showed that the expression level of miR-29b in
twenty cases of paraffin NSCLC tissues was (−1.893 ±
1.367), significantly lower than that in the adjacent lung
tissue (−0.605 ± 0.639; P = 0.001, t = −3.817). The expres-
sion level of miR-29b in ten cases of fresh non-small cell
lung cancer tissues was (−1.996 ± 0.460), significantly
lower than that in the adjacent lung tissue (−0.463 ±
0.257; P < 0.001, t = −9.016).
Data present from Table 1 showed the clinicopatho-
logic characteristics of miR-29b expression in NSCLC
patients. There was no significant relationship of miR-
29b expression with age (P = 0.578), gender (P = 0.862),
histology (P = 0.625) and differentiation (P = 0.891);
while miR-29b expression was found had significant re-
lationships with lymphatic metastasis (P = 0.004) and
clinic stage (P = 0.031). Spearman rank correlation ana-
lysis was applied to analyze the expression levels of miR-
29b, tumor stage and lymphatic metastasis in NSCLC
tissues. The expression of miR-29b was positively corre-
lated with lymphatic metastasis (r = −0.547, P = 0.043).
Based on our findings, the expression of miR-29b is
down-regulated in NSCLC compared to normal tissues
and significantly associated with metastasis.
Fig. 1 Integrated method for screening potential miRNAs and target genes related to NSCLC metastasis. Dendrogram of differentially expressed
miRNAs (a) and metastasis-related genes (b) between primary cultured CD133-positive/negative lung adenocarcinoma cells. (c), The overlap of
target genes predicted by microRNA.org, TargetScan and Pictar datebases
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Fig. 2 Expression of miR-29b in NSCLC cell lines and paired NSCLC tissues. a, Quantitative RT-PCR analysis of miR-29b expression levels in NSCLC cell
lines and immortalized human bronchial epithelial cell line were shown relative to U6 snRNA as an internal control. b, Quantitative RT-PCR analysis of
miR-29b levels in 20 pairs of paraffin-embedded NSCLC tissues. c, Quantitative RT-PCR analysis of miR-29b levels in 10 pairs of fresh NSCLC tissues
Table 1 Clinicopathologic characteristics of miR-29b expression
in NSCLC patients
Features Case(n) Percent -△CT P
Age
>60 14 46.67 −2.044 ± 1.311
= < 60 16 53.33 −1.807 ± 0.989 0.578
Gender
Male 16 53.33 −1.883 ± 0.722
Female 14 46.67 −1.957 ± 1.508 0.862
Histology
Squamous cancer 4 13.33 −2.182 ± 0.858
Adenocarcinoma 26 86.67 −1.877 ± 1.182 0.625
Differentiation
Well + Moderate 21 70 −1.931 ± 1.344
Poor 9 30 −1.886 ± 0.401 0.891
Clinic Stage
I 10 33.33 −1.122 ± 0.638
II 9 30 −1.881 ± 0.453
III 11 36.67 −2.671 ± 1.398 0.004
Lymphatic Metastasis
No 16 53.33 −1.505 ± 0.799
Yes 14 46.67 −2.389 ± 1.302 0.031
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invasion in A549 cells
Cell proliferation, migration, and invasion are key steps
in tumor metastasis required by tumor cells for meta-
static progression in target microenvironments. In A549
cells, after miR-29b lentivirus and negative control (NC)
infection, a visible significant difference was seen with
fewer miR-29b transfected cells counted than NC trans-
fected cells in migration and invasion assays (Fig. 3a).
Consistently, compared with negative controls, the pro-
liferation abilities of A549-miR-29b cells were signifi-
cantly decreased (Fig. 3b, *P < 0.05, **P < 0.01). Nude
mice xenograft model was subsequently applied to
evaluate the effect of miR-29b on tumorigenicity (Fig. 3c).
Statistical analysis of the mean tumor volume (cm3)
demonstated that miR-29b lentivirus infection inhibited
the tumor growth comparing to the control groups
(Fig. 3d, **P < 0.01). These findings might indicate that
upregulation of miR-29b had a potential to inhibit of
metastasis of NSCLC.
miR-29b deficiency alters the metastasis ability of H460 cells
In the present study, we have observed an apparent en-
dogenous expression of miR-29b in H460 cells. There-
fore, miR-29b silencing with antisense oligonucleotides
Fig. 3 miR-29b inhibited cell proliferation, migration and invasion in vitro. a, In Matrigel invasion and transwell migration assay, LV-miR-29b infected
A549 cells vs NC infected cells in a 200× light scope after crystal violet staining. Cells were counted in a light scope in four random views. b, miR-29b
decreased cellular proliferation ability in A549 cells by CCK8 assay. *P < 0.05, **P < 0.01, compared with blank and NC groups. c, Photographs
of subcutaneous tumors of mice injected with A549 cells that infected with LV-miR-29b compared to NC infected cells treatment. d, Subcutaneous
tumors growth curves of each group after injection. ** P < 0.01, compared with blank and NC groups
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cell migration and invasion ability was promoted in
miR-29b inhibitor group comparing to the control
groups. miR-29b inhibitor also increased H460 cells pro-
liferation in a time-dependent manner (Fig. 4b, *P < 0.05,
**P < 0.01). Compared to H460 cells or H460-LV-NC
cells group, tumor growth rates and tumor volumes of
H460-LV-miR-29b-inhibitor cells group were signifi-
cantly increased (Fig. 4c, d, *P < 0.05). Collectively, these
observations suggested that miR-29b suppressed growth
and metastasis of NSCLC cell in vitro and in vivo.
Effect of miR-29b on cell migration and invasion ability in
A549-L and A549-H cells
High-invasion (A549-H) and low-invasion (A549-L)
NSCLC cell sublines from A549 cells were created by
using the 10 times repeated transwell assay. Herein, the
role of miR-29b in cell migration and invasion was eval-
uated these two kinds of cells. miR-29b was found
down-regulated in A549-H cells and up-regulated in
A549-L cells. The images showed that miR-29b overex-
pression inhibited A549-H cells migration and invasion(Fig. 5a). The result of statistical analysis was showed in
Fig. 5b (*P < 0.05). As expected, miR-29b inhibitor pro-
moted cell migration and invasion (Fig. 5c) of A549-L
cells. The result of statistical analysis was showed in
Fig. 5d (*P < 0.05). These data confirmed that miR-29b
was a metastasis suppressor in NSCLC cells.
MMP2 as a target gene of miR-29b in NSCLC
To further explore the mechanisms of miR-29b which
suppresses lung cancer cell invasion and metastasis, we
analyzed probable down stream tumor metastasis-
related genes. Computational prediction was used to find
out the most likely target genes. The taregets of miR-
29b were analyzed by the TargetScan, PicTar and Mi-
Randa databases. The analysis revealed that miR-29b
bound to the MMP2 3’ UTR with a partially comple-
mentary pattern (Fig. 6a). After A549 cells were infected
with lentivirus LV-miR-29b, the expression of miR-29b
was increased significantly compared with the NC and
Blank groups (Fig. 6b, *P < 0.05). As expected, the ex-
pression of MMP2 mRNA was down-regulated signifi-
cantly (Fig. 6c, *P < 0.05). Moreover, western blot results
Fig. 4 miR-29b deficiency altered the metastasis ability of H460 cells. a, In Matrigel invasion and transwell migration assay, LV-miR-29b inhibitor
infected H460 cells vs NC infected cells in a 200× light scope after crystal violet staining. Cells were counted in a light scope in four random
views. b, miR-29b inhibitor increased cellular proliferation ability in H460 cells by CCK8 assay. *P < 0.05, **P < 0.01, compared with blank and NC
groups. c, Photographs of subcutaneous tumors of mice injected with H460 cells that infected with LV-miR-29b inhibitor compared to NC infected cells
treatment. d, Subcutaneous tumors growth curves of each group after injection. **P < 0.01, compared with blank and NC groups
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significantly (Fig. 6d). Similar results were obtained
when miR-29b inhibitor was transfected into the H460
cells, the miR-29b expression level decreased and
MMP2 mRNA was up-regulated significantly after 48 h
transfection compared with the NC group and Blank
groups (Fig. 6b, c, *P < 0.05). MMP2 protein expression
was increased after 72 h transfection (Fig. 6d). These
findings indicated that miR-29b regulated MMP2 ex-
pression negatively. To verify whether MMP2 is a direct
target of miR-29b, the 3’UTR of MMP2 cDNA was
cloned into the downstream region of the luciferase re-
porter gene (psiCHECK-2-Wt-MMP2-3’UTR) and co-
transfected this vector into 293-T cells with miR-29b
mimic (Additional file 5: Figure S1A, B). The luciferase
reporter gene study further confirmed that miR-29b
bound directly to wild-type MMP2 3’ UTR to inhibit the
luciferase activity. To confirm the sequence-specific re-
pression of miR-29b, we designed mutated versions of
psiCHECK-2-Wt-MMP2-3’UTR carrying 4-bp substitu-
tions in miR-29b target site (psiCHECK-2-Mut-MMP2-
3’UTR) (Additional file 5: Figure S1C, D). There was noinhibition effect on the following site-specific mutagen-
esis of the miR-29b MMP2 3’ UTR binding sites (Fig. 6e,
*P < 0.05), indicating that miR-29b directly regulated the
target gene MMP2 negatively in NSCLC.
miR-29b affected PTEN expression by binding directly
with the PTEN 3’ UTR
TargetScan indicated that miR-29b had two highly con-
served PTEN 3’ UTR binding sites (Fig. 7a). Luciferase
reporter activity assay was used to determine whether
miR-29b regulates PTEN directly via the software-
predicted binding sites. Figure 7b depicted the insertion
sites of wild-type and mutant PTEN 3’ UTR into the
constructed plasmids. The 1500-bp fragment of the
3’UTR region of PTEN mRNA that included the pre-
dicted miR-29b recognition site was subcloned and
inserted into a luciferase reporter plasmid (Additional
file 6: Figure S2A, B). Two miR-29b binding sites in the
3’UTR region of PTEN were mutated to obtain
psiCHECK-2-Mut1-3-PTEN-3’UTR plasmid (Additional
file 6: Figure S2C–F). Following detection, the luciferase
activity in the co-transfected with wild-type PTEN-luc
Fig. 5 Effect of miR-29b on migration and invasion ability of A549-L and A549-H cells. a, In Matrigel invasion and migration assay, LV-miR-29b
infected A549-H cells vs NC infected cells in a 200× light scope after crystal violet staining. b, Cells were counted in a light scope in four random
views (*P < 0.05, n = 4). c, In Matrigel invasion and migration assay, miR-29b inhibitor infected A549-L cells vs NC infected in a 200× light scope
after crystal violet staining. d, Cells were counted in a light scope in four random views (*P < 0.05, n = 4)
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creased compared with that in the blank or NC groups
(*P < 0.05). The luciferase activity in the co-transfected
with mutant-type1 or mutant-type2 PTEN-luc reporter
and miR-29b mimic group was also significantly de-
creased compared with that in the blank or NC groups
(*P < 0.05). However, there were no significant changes
in the co-transfected with mutant-type3 PTEN-luc re-
porter and miR-29b mimic group and the blank or NC
groups (Fig. 7c, *P < 0.05). This result proved that miR-
29b bound directly to both PTEN 3’UTR binding sites.
Therefore, PTEN was a direct target of miR-29b. The in-
fluence of miR-29b on PTEN mRNA and protein ex-
pression levels were also evaluated in the A549 and
H460 cells, There were no obvious changes on PTEN
mRNA and protein expression levels in LV-miR-29b in-
fected A549 cells or in miR-29b inhibitor transfected
H460 cells compared with the NC or Blank groups
(Fig. 7d, e).
Discussion
In the present study, we provided evidence that miR-29b
expression in high-metastatic CD133-positive A549 lines
was down-regulated when compared to miR-29bexpression in paired low-metastatic CD133-negtive
A549 cell lines, miR-29b was confirmed directly targeted
3’-UTR of PTEN and MMP2 mRNAs and down-
regulated MMP2 protein expression to suppress lung
cancer metastasis in vitro and in vivo.
As a MMP superfamily member, MMP2 specifically
degrades type IV collagen, a major component of the
extracellular matrix and basal lamina, and is a major fac-
tor in tumor invasion and angiogenesis [19]. It has been
demonstrated that high MMP2 expression is an inde-
pendent prognostic factor in NSCLC and is closely re-
lated to clinical stage, pathological grade, lymphatic
metastasis, and prognosis [20]. The regulatory mecha-
nisms of a miRNA could differ among different microen-
vironments, miR-29b is upregulated in metastatic breast
cancer tissues and indolent lymphocytic leukemia, func-
tioning as an oncogene [21, 22]. However, miR-29b is
down-regulated in lung carcinoma tissues [23]. In our
study, low-level expression of miR-29b in NSCLC tissues
was significantly associated with lymphatic metastasis.
We performed gain-of-function in A459 cells and loss-
of-function in H460 cells of miR-29b. Our data demon-
strated that miR-29b inhibited in vitro cell proliferation,
invasion and migration and in vivo suppressed NSCLC
Fig. 6 miR-29b directly targets 3’-UTR of the MMP2 gene. a, Predicted binding sites in the 3’-UTR of MMP2 mRNA and seed sequence of miR-29b
by TargetScan. b, Quantitative RT-PCR analysis of miR-29b expression levels in A549 and H460 cell lines after infection LV-miR-29b or miR-29b
inhibitor, respectively. c, Quantitative RT-PCR analysis of MMP2 mRNA expression levels in A549 and H460 cell lines after infection LV-miR-29b or
miR-29b inhibitor, respectively. d, Western blots analysis of MMP2 expression levels in A549 and H460 cell lines following LV-miR-29b or miR-29b
inhibitor infection, respectively. e, Dual luciferase activity indicating relative luciferase activity following co-transfection with psiCHECK-2-Wt-MMP2-
3’UTR or psiCHECK-2-Mut-MMP2-3’UTR and miR-29b mimic. Results are presented as means ± SEM (*P < 0.05, n = 3)
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the dual-luciferase reporter assay demonstrated that
miR-29b inhibited the expression of luciferase gene con-
taining the 3’-UTR of PTEN and MMP2. Western blotting
indicated that miR-29b down-regulated the endogenous
protein expression of MMP2. Based on these results, It’s
concluded that miR-29b was related to metastasis in
NSCLC.
PTEN regulates tumor cell growth, cell cycle, apop-
tosis, and metastasis by regulating multiple signal trans-
duction pathways negatively [24, 25]. All three databases
used (TargetScan, PicTar, miRanda) identified the two
PTEN 3’ UTR miR-29b binding sites. Both sites were
conserved among different species and fully complemen-
tary to the miR-29b seed sequence, corresponding to thebasic rules for predicting miRNA target genes [26]. Our
present results showed that miR-29b bound directly to
the two PTEN 3’ UTR binding sites and PTEN was a
miR-29b target gene. Through miR-29b overexpression
or knockdown analysis, the fact was determined that
miR-29b variations were not accompanied with the alter-
ation of PTEN expression. As multiple miRNAs could
regulate the same target gene [27], we speculate that
other miRNAs could also bind directly to the PTEN 3’
UTR and regulating PTEN expression. Several research
reported that PTEN function as a target gene of miR-21
[28], miR-214 [29], miR-494 [30], miR-26a [31], miR-144
[32] and miR-153 [33]. of these, miR-21, miR-214, and
miR-494 are upregulated in NSCLC. Another reason
that might explain our contrasting findings was that
Fig. 7 miR-29b directly targets 3’-UTR of the PTEN gene. a, Predicted binding sites in the 3’-UTR of PTEN mRNA and seed sequence of miR-29b
by TargetScan. b, Schematic diagrams of miR-29b and PTEN 3’ UTR binding and wild-type and mutated psiCHECK-2-PTEN-3’UTR sequences.
c, Relative luciferase activity evaluated by dual luciferase reporter genes following co-transfection with psiCHECK-2-Wt-PTEN-3’UTR or psiCHECK-2-
Mut1-3-PTEN-3’UTR and miR-29b mimic, respectively. Results are presented as means ± SEM (*P < 0.05, n = 3). d, Western blots analysis of PTEN
expression levels in A549 and H460 cell lines following LV-miR-29b or miR-29b inhibitor infection, respectively. e, Quantitative RT-PCR analysis of
PTEN mRNA expression levels in A549 and H460 cell lines following LV-miR-29b or miR-29b inhibitor infection, respectively
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p53 expression [34]. P53 activates PTEN transcription,
binding directly to the PTEN promoter and activating
PTEN expression [35]. PTEN gene was not only indir-
ectly regulated by miR-29b-p53-PTEN positively, but
also directly regulated by miR-29b negatively. The inhib-
ition of Sp1 by miR-29b resulted in the upregulation of
PTEN in tongue squamous cell carcinoma [36].
Conclusion
In summary, our studies demonstrated that down-regulated
miR-29b expression was found to be associated with in-
creased MMP2 expression in CD133-positive NSCLC cells
through microarrays and bioinformatics analysis. miR-29bplayed a strong inhibitory role in tumor metastasis. We
provided important evidence that miR-29b could sup-
press NSCLC cells proliferation, migration and invasion
by targeting the 3’-UTR of MMP2 and PTEN mRNA to
down-regulate MMP2 protein expression. Our findings
provided novel evidence for the involvement of miR-
29b in NSCLC metastasis, and suggested that miR-29b
could be a potential new target for treatment of NSCLC
metastasis.
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